Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls.

ABSTRACT:

Background

Immunocompromised patients are at particular risk of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection and previous findings suggest that the infection or vaccination induced immune response decreases over time. Our main goal was to investigate the SARS-CoV-2-specific immune response in rheumatoid arthritis patients and healthy controls over prolonged time.

Methods

The SARS-CoV-2-specific humoral immune response was measured by Elecsys Anti-SARS-CoV-2 Spike (S) immunoassay, and antibodies against SARS-CoV-2 nucleocapsid protein (NCP) were also evaluated by Euroimmun enzyme-linked immunosorbent assay (ELISA) test. The SARS-CoV-2-specific T-cell response was detected by an IFN- γ release assay.

Results

We prospectively enrolled 84 patien

SUBMITTER: Nemeth D 

PROVIDER: S-EPMC11190160 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature